Inflammation Peptides

A pentadecapeptide derived from human gastric juice, studied for tissue repair and gut-protective properties.

A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery.

A naturally occurring copper-binding peptide studied for skin regeneration, wound healing, and anti-aging effects.

A thymic peptide approved in some countries for immune modulation, studied for viral infections and cancer adjunct therapy.

A tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties.

A human antimicrobial peptide studied for innate immunity, wound healing, and biofilm disruption.

A semi-synthetic polysaccharide FDA-approved for interstitial cystitis and studied for joint health applications.

A non-erythropoietic EPO analog studied for nerve repair and neuropathic pain conditions.

A neuropeptide with broad neuroimmune functions, studied for inflammatory conditions and nerve repair.

A multi-peptide blend combining BPC-157, TB-500, GHK-Cu, and KPV for comprehensive tissue repair and anti-inflammatory support.

A combined formulation of BPC-157 and TB-500, the two most commonly paired tissue repair peptides.

A synthetic peptide tight junction regulator in clinical trials for celiac disease, designed to prevent intestinal permeability caused by gluten exposure.

A brain-targeting tetrapeptide studied for neuroprotection and targeted drug delivery to injured brain and spinal cord tissue.

An endogenous cardiovascular peptide that signals through the APJ receptor, studied for heart failure, cardiac repair, and cardioprotection with multiple synthetic analogs in clinical development.

The first FDA-approved targeted oral macrocyclic peptide — an IL-23 receptor antagonist for moderate-to-severe plaque psoriasis, marking a new era for oral peptide therapeutics.

A synthetic 15-amino-acid peptide derived from the IL-10 receptor alpha chain, granted FDA breakthrough therapy status for systemic lupus erythematosus (SLE) after Phase III trial success.